PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsCystic fibrosis drug double-up does well in trial

BioNews

Cystic fibrosis drug double-up does well in trial

Published 27 June 2014 posted in News and appears in BioNews 760

Author

Isobel Steer

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A combination of two gene-targeting drugs significantly increases the lung function of cystic fibrosis patients, a clinical trial shows....

A combination of two gene-targeting drugs significantly increases the lung function of cystic fibrosis (CF) patients, clinical trials show.

Although the results appear to be 'at the low end of what some doctors would consider meaningful', according to The New York Times, they have sparked a flurry of interest from investors in Vertex Pharmaceuticals, the company behind the drugs.

The drugs are not a cure for CF, but rather aim to improve patient
quality of life. Speaking during a webcast, Vertex chief executive Dr Jeffrey Leiden
said: 'For these patients every improvement that they have in lung function,
and every day they don't spend in the hospital, and every pound they gain is
meaningful to them and their families. And that's why we're so pleased with the
results'.

CF is an genetic condition in which the lungs and digestive system become clogged with thick,
sticky mucus. A few decades ago, most patients would die from complications
before adulthood but now, according to The Cystic Fibrosis Trust, 'more than half of the CF population in the UK will live
past 41'. Over 10,000 people have CF in the UK.

CF is caused by a malfunctioning protein, called CFTR. This protein can
be inactivated by mutation in several genes, which means there are multiple
genetic targets for drug developers. One of the drugs in the combination, ivacaftor
(marketed as Kalydeco), has been approved since 2012, but is
only effective for the 2,200 patients worldwide with the rare G551D mutation.

By combining ivacaftor with another Vertex drug, lumacaftor, the goal is
to extend treatment to half of all CF patients who possess two copies of the F508del
mutation.

The average lung capacity improvement of the F508del patients was only a
third of the ten percent improvement experienced by G551D patients taking
Kalydeco. But the 1,100 patients in the two phase III clinical trials gained an
average of 1.6 pounds in weight, and were less likely to catch infections
resulting in hospitalisation.

'On average, people with CF who have two copies of the F508del mutation
lose nearly two percent of their lung function each year, underscoring the
urgent need for new medicines', said Dr Bonnie Ramsey, professor at the
University of Washington School of Medicine and lead investigator on one of the
trials.

Discussing the lower-than-ideal
increase in lung capacity with The New York Times, Professor Ramsey said: 'Would
I have rather seen six, seven percent? Of course'. But maintained that the results
represented a 'very positive step forward'.

Some questions remain about the study: why the drugs' effect was not
dose-dependent; and why, paradoxically, shortness of breath was noted as a side
effect.

Although the data have not yet been analysed by the Food and Drug
Administration, Vertex's stock price has risen sharply - a sign that industry
investors are confident the drug combination will soon be available
commercially.

In a statement included on Vertex's press release, Dr Robert Beall, president
and CEO of the Cystic Fibrosis Foundation in the USA said the results 'mark an exciting day for the CF community and validate
our more than 30-year commitment to develop medicines that target the
underlying basic defect of CF for all people with this devastating disease'.

According to Forbes magazine, the studies also
serve to validate a novel research technique developed by Dr Fred Van Goor, the
head of Vertex's research programme - a cell culture assay nicknamed the 'lung-in-a-dish'.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
3 July 2015 • 2 minutes read

Gene therapy for cystic fibrosis shows promise

by Dr Nicoletta Charolidi

A new gene therapy technique for treating cystic fibrosis has shown potential in a new study...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 February 2013 • 2 minutes read

Major gene therapy trial for cystic fibrosis given go-ahead

by Heidi Colleran

The largest trial for a gene therapy for cystic fibrosis (CF) will begin in the UK this month. Coordinated by the UK Cystic Fibrosis Gene Therapy Consortium (GTC), 130 patients will be recruited and given working copies of the defective gene that leads to their condition...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
1 November 2012 • 2 minutes read

DNA affecting the severity of cystic fibrosis discovered

by Dr Kimberley Bryon-Dodd

Two genetic regions that might explain some differences in disease severity in cystic fibrosis (CF) patients have been identified by US and Canadian researchers. The two regions contain genes that can modify lung function...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
18 November 2010 • 2 minutes read

Drug helps to partially reverse cystic fibrosis genetic defect

by Dr Lux Fatimathas

American researchers have successfully treated cystic fibrosis patients with a new drug targeting the cause of the disease. Patients carrying a common genetic mutation associated with cystic fibrosis were treated with the drug VX-770...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
13 August 2010 • 1 minute read

Newborns to be screened for genetic conditions

by Dr Lux Fatimathas

Newborn babies showing signs of liver disorders will be screened for 92 genetic conditions, as part of a trial launching next month at Birmingham Children's Hospital. Newborns will be screened for multiple conditions with a single test using gene chip technology....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Second IVF company to be floated sees share prices grow

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

4 July 2022 • 2 minutes read

Genetic and epigenetic causes of IVF embryo arrest discovered

4 July 2022 • 2 minutes read

Dutch donor-conceived people seek answers

4 July 2022 • 2 minutes read

Genetic variant increases Alzheimer's risk, especially in women

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856